Carteyva is a next-generation CD19 CAR T cell therapy approved in China for the treatment of large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. Developed and enhanced from Juno Therapeutics’ pioneering CAR-T technology platform, Carteyva offers durable remission with a safer profile—delivering fewer and milder side effects compared to earlier treatments.
Exclusively available in China, this state-of-the-art therapy is also offered at an accessible and affordable cost.
For more information on how to access Carteyva treatment, please contact us at info@cartcellschina.com.
A patient with high-risk POD24 follicular lymphoma achieved durable complete remission after treatment with Carteuva CD19 CAR-T therapy. This case highlights the growing role of CAR-T therapy in patients with early relapse and limited treatment options.
CAR-T cell therapy for large B-cell lymphoma offers a breakthrough option for relapsed or refractory cases, using engineered immune cells to target CD19-positive cancer cells with high remission rates.
CAR-T cell therapy has transformed the treatment landscape for relapsed and refractory mantle cell lymphoma. Learn how this innovative immunotherapy works, who may benefit, and what patients can expect when seeking treatment in China.
New Phase II data from China demonstrate that relma-cel CAR-T therapy delivers high response rates and durable survival in heavily pretreated relapsed/refractory mantle cell lymphoma patients.
Alan from the Phillippines sharing his experience of getting CAR-T cell therapy at our affiliated medical center.
China’s domestically developed CAR-T therapy, Carteyva, is giving new hope to patients with relapsed/refractory lymphoma. From a personalized treatment process to promising survival data, this breakthrough cell therapy is reshaping the future of cancer care in China.
Relma-cel CAR-T therapy achieved complete remission in a high-risk, elderly R/R DLBCL patient, offering new hope where standard treatments failed.
In this video, we share the courageous journey of a patient diagnosed with mantle cell lymphoma (MCL), a rare and aggressive type of non-Hodgkin lymphoma. After undergoing multiple rounds of
Discover how CARTEYVA, a CD19-directed CAR-T therapy is advancing treatment for follicular lymphoma with promising results and local availability in China.
NMPA granted Breakthrough Therapy Designation for Carteyva (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) .
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.